Context Therapeutics (CNTX) AI Stock Analysis

• Market Cap: $56.29M
• Dividend Yield: N/A
• Average Volume (3M): 306.14K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.21
• Revenue Growth: N/A
• EPS Growth: 65.02%
• Country: US
• Employees: 12
• Sector: Healthcare
• Sector Strength: 47
• Industry: Biotechnology
• EPS (TTM): -0.05
• Shares Outstanding: 89,704,190
• 10 Day Avg. Volume: 167,319
• 30 Day Avg. Volume: 306,144
• PEG Ratio: 0.00
• Price to Book (P/B): -2.33
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -19.71
• Enterprise Value/Market Cap: 1.38
• Enterprise Value/Revenue: 2.04K
• Enterprise Value/Gross Profit: -30.18K
• Enterprise Value/Ebitda: -0.68
• 1Y Price Target: $4.50
• Price Target Upside: 614.29% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5

• Rating: 37 Underperform
• Price Target: ―

Context Therapeutics has significant financial challenges, with no revenue and consistent losses, heavily weighing down its overall score. Technical analysis shows neutral market momentum, while valuation metrics highlight unprofitability. However, the recent initiation of a Phase 1 trial offers some hope for future growth. Collectively, these factors result in a low overall stock score, reflecting the company's current financial instability and speculative potential.

Positive Factors

Clinical Trials

The initiation, enrollment, and dosing of CT-95 in trials are seen positively, especially since it was licensed by the company recently.

Financial Stability

Context remains well-capitalized with $94.4M in cash, providing financial stability and runway into 2027.

Negative Factors

Market Conditions

Broad market headwinds continue in 2025 including continued challenging financing conditions and changes to NASDAQ/NYSE listing rules, pressuring small/micro cap biotech stocks.

Stock Performance

Context shares have decreased over 11%, highlighting concerns about the company's stock performance compared to market indices.

Context Therapeutics Business Overview & Revenue Model

Company Description

Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for gynaecologic cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

How the Company Makes Money

Context Therapeutics makes money primarily through the development and commercialization of its proprietary drug candidates. The company engages in strategic partnerships and collaborations with other pharmaceutical firms to advance its clinical trials and bring its therapies to market. Revenue is generated through milestone payments, licensing agreements, and potential future sales of approved drugs. Additionally, Context Therapeutics may receive funding through government grants and private investments to support its research and development activities.

Context Therapeutics Financial Statement Overview

Summary

Context Therapeutics faces severe financial challenges with no revenue generation and persistent losses. The balance sheet shows some improvement with increased equity, but the company remains reliant on external financing to bridge operational cash deficits. The financial health of the company is concerning given the industry dynamics and lack of profitability.

Income Statement

The income statement reveals significant challenges with no revenue generation and consistently negative net income, EBIT, and EBITDA over the years. The company is struggling with profitability and growth, reflected in the absence of gross profit and net profit margins.

Balance Sheet

The balance sheet shows an improvement in stockholders' equity and a reduction in liabilities over the years. However, the absence of revenue and high levels of net debt in past years highlight potential solvency issues. The debt-to-equity ratio has improved but remains a concern for financial stability.

Cash Flow

The cash flow statement indicates substantial negative free cash flow and operating cash flow, suggesting insufficient cash generation from operations. Although there is a recent influx of financing cash flow, the company heavily depends on external financing, posing risks to cash flow sustainability.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-2.57K	0.00	-12.04K	-9.27K	0.00	0.00
EBITDA	-31.62M	-26.67M	-25.06M	-14.83M	-10.53M	-2.57M
Net Income	-27.64M	-26.73M	-23.96M	-14.84M	-10.46M	6.64M
Balance Sheet
Total Assets	92.97M	98.13M	16.06M	37.97M	51.31M	467.34K
Cash, Cash Equivalents and Short-Term Investments	89.35M	94.43M	14.45M	35.50M	49.64M	341.04K
Total Debt	193.71K	219.38K	0.00	55.08K	0.00	5.95M
Total Liabilities	1.98M	2.86M	4.19M	3.21M	3.03M	17.39M
Stockholders Equity	90.98M	95.27M	11.87M	34.76M	48.27M	-16.92M
Cash Flow
Free Cash Flow	-587.38K	-29.31M	-21.05M	-14.09M	-9.05M	-1.03M
Operating Cash Flow	-546.11K	-14.56M	-21.05M	-13.55M	-8.80M	-1.03M
Investing Cash Flow	-14.79M	-14.76M	0.00	-536.84K	-250.00K	0.00
Financing Cash Flow	109.28M	109.29M	0.00	-102.07K	58.39M	1.15M

Context Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.63
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CNTX, the sentiment is Negative. The current price of 0.63 is above the 20-day moving average (MA) of 0.62, below the 50-day MA of 0.71, and below the 200-day MA of 1.17, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 47.82 is Neutral, neither overbought nor oversold. The STOCH value of 57.14 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CNTX.

Context Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	60 Neutral	HK$15.27B	5.80	-7.43%	4.22%	11.60%	-21.06%
IMAB	45 Neutral	$184.72M	―	-22.38%	―	―	―
SRZN	43 Neutral	$75.44M	―	-456.32%	―	―	0.13%
ZURA	43 Neutral	$64.97M	―	-62.34%	―	―	86.65%
CNTX	37 Underperform	$56.29M	―	-55.59%	―	―	65.02%
BDTX	33 Underperform	$141.02M	42.14	4.14%	―	―	33.97%
ELTX	30 Underperform	$123.50M	―	-744.59%	―	―	27.65%

Context Therapeutics Corporate Events

Context Therapeutics Begins Phase 1 Trial for CT-95

On April 9, 2025, Context Therapeutics announced the dosing of the first patient in its Phase 1 clinical trial for CT-95, a mesothelin x CD3 T cell engaging bispecific antibody. This marks Context’s second active clinical trial in 2025, following CTIM-76, and signifies progress in their mission to develop precision immunotherapies for solid tumors. The trial aims to evaluate the safety and efficacy of CT-95 in patients with mesothelin-expressing advanced solid tumors, with initial data expected in mid-2026.

Spark’s Take on CNTX Stock

According to Spark, TipRanks’ AI Analyst, CNTX is a Underperform.

Context Therapeutics faces significant financial challenges with no revenue generation and persistent losses, weighing heavily on its stock score. The technical analysis shows a bearish trend, and valuation metrics indicate unprofitability. However, positive corporate events, such as advancements in their clinical pipeline and leadership changes, offer some potential for future growth. Overall, the company’s financial instability and current market position limit its stock attractiveness.

To see Spark’s full report on CNTX stock, click here.